Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Event Reporting
        • Educational Events
        • Non-Price Benefit Reports
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / Generic Medicines Facts / Topics / IGBA

IGBA

GBMA is an associate member of the International Generic and Biosimilar Medicines Association (IGBA)

httpss://www.youtube.com/watch?v=36XeApjBG-o

 

Originally called the International Generic Pharmaceutical Alliance (IGPA), IGBA was founded in March 1997 as an international network of generic medicines associations. The name of the organization was changed in September 2015 to the International Generic and Biosimilar Medicines Association to reflect the evolving nature of the industry.

IGBA is committed to promoting generic and biosimilar medicines, and exchanging information worldwide. IGBA consists of the following associations:

  • Canadian Generic Pharmaceutical Association (CGPA-Canada)
  • Medicines for Europe (Europe)
  • Generic Pharmaceutical Association (GPhA-USA)
  • Japan Generic Medicines Association  (JGA-Japan)
  • Jordanian Association of Pharmaceutical Manufacturers (JAPM-Jordan)
  • National Association of Pharmaceutical Manufacturers (NAPM-South Africa)
  • Taiwan Generic Pharmaceutical Association (TGPA-Taiwan)
  • In addition, the generic medicines associations of Australia, Brazil and Mexico are Associate Members

Through its constituent member associations, the IGBA maintains constant dialogue with the ICH, WHO, WTO, WIPO and other international organizations.

IGBA members share a set of common principles:

Access to affordable quality medicines 

  • We believe that seeking to improve access to affordable quality medicines worldwide and promote the quality, safety and efficacy of generic medicines is of utmost importance.

Ensure timely access for patients 

  • We all know how difficult it is to strike a balance between patent protection and free competition, which is why achieving balanced intellectual property rights in our sector will ensure timely access for patients to our products.

Global harmonisation of regulations relating to quality 

  • A top priority is to promote the global harmonisation of regulations relating to the quality of generic products, especially ensuring strict adherence to bioequivalence standards.

Improving regulatory and legal expertise 

  • We have worked very hard to provide guidance to international organisations and national governments to improve their regulatory and legal expertise relating to the manufacture, registration and marketing of high quality generic medicines, and promotion of uniform and effective GMP standards and quality controls.

Prevent the production and trade of counterfeit versions 

  • We are concerned with the counterfeiting of medicines, which is a criminal act that puts the health and life of patients in jeopardy. As an alliance, we are fighting in favour of strict and effective regulatory controls to prevent the production and trade of counterfeit versions of all medicines and their APIs.

 

Our Members

Juno
Juno
Sandoz logo
Sandoz logo
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
generic_partners
generic_partners
southern_cross
southern_cross
commercial_eyes
commercial_eyes
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

Announcement of Independent Chair

December 9, 2020

9 December 2020 Canberra, ACT Global health policy powerhouse, Jane Halton AO PSM, joins GBMA as its inaugural Independent … More...

Confidence in biosimilar medicines, amongst specialists, GP’s and Pharmacists

December 8, 2020

12 November 2020 Canberra, ACT New research shows prescriber … More...

IGBA Launches First Global Biosimilars Week

December 7, 2020

16 November 2020 Geneva, Switzerland Today the International Generic and … More…

© 2021 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us